Larimar Therapeutics (LRMR) EBITDA (2013 - 2026)
Larimar Therapeutics' (LRMR) quarterly EBITDA came in at -$64.0 million in Q4 2025, down 104.58% YoY from $1.4 billion in Q4 2024, and down 29.33% on a QoQ basis from -$49.5 million in Q3 2025.
Larimar Therapeutics (LRMR) EBITDA (2013 - 2026) Analysis & Trends
Larimar Therapeutics (LRMR) has 13 years of EBITDA data on file, last reported at -$64.0 million in Q4 2025.
- Quarterly EBITDA fell 104.58% year-over-year to -$64.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$172.5 million (down 89.79% YoY) and the FY2025 annual result came in at -$172.5 million, down 89.79% from the prior year.
- EBITDA slipped to -$64.0 million in Q4 2025, from -$49.5 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$7.6 million in Q1 2023 to a low of -$64.0 million in Q4 2025.
- A 5-year average of -$19.6 million and a median of -$13.4 million in 2021 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA soared 49.12% — and 2025, when it tumbled 171.02%.
- Tracing LRMR's EBITDA over 5 years: stood at -$9.1 million in 2021, then declined by 14.89% to -$10.4 million in 2022, then slumped by 35.66% to -$14.2 million in 2023, then slumped by 120.96% to -$31.3 million in 2024, then sank by 104.58% to -$64.0 million in 2025.
- The last three EBITDA figures came in at -$64.0 million (Q4 2025), -$49.5 million (Q3 2025), and -$27.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Larimar Therapeutics | 452.93 Mn | 296.66 Mn | - | -34.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.35 Mn |
| Dec 31, 2025 | -64.02 Mn |
| Sep 30, 2025 | -49.50 Mn |
| Jun 30, 2025 | -27.79 Mn |
| Mar 31, 2025 | -31.19 Mn |
| Dec 31, 2024 | -31.29 Mn |
| Sep 30, 2024 | -18.26 Mn |
| Jun 30, 2024 | -24.60 Mn |
| Mar 31, 2024 | -16.73 Mn |
| Dec 31, 2023 | -14.16 Mn |
| Sep 30, 2023 | -10.34 Mn |
| Jun 30, 2023 | -9.62 Mn |
| Mar 31, 2023 | -7.64 Mn |
| Dec 31, 2022 | -10.44 Mn |
| Sep 30, 2022 | -8.51 Mn |
| Jun 30, 2022 | -8.69 Mn |
| Mar 31, 2022 | -8.89 Mn |
| Dec 31, 2021 | -9.09 Mn |
| Sep 30, 2021 | -16.73 Mn |
| Jun 30, 2021 | -12.54 Mn |